Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesEfficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study
Journal of Clinical Oncology, 06/22/09
Zhu AX et al. – In a phase II study, sunitinib shows evidence of modest antitumor activity in advanced hepatocellular carcinoma (HCC) with manageable adverse effects. Rapid changes in tumor vascular permeability and circulating inflammatory biomarkers are potential determinants of response and resistance to sunitinib in HCC.
Methods- Aim was to assess in pts with advanced HCC:
- Safety and efficacy of sunitinib and
- Explore biomarkers for sunitinib response
- Pts received sunitinib 37.5 mg/d for 4 wks followed by 2 wks of rest per cycle
- Primary end point: progression-free survival (PFS)
- Functional MRI was used to evaluate vascular changes in HCC after sunitinib treatment
- Circulating molecular and cellular biomarkers were evaluated before and at 6 time points after sunitinib treatment
- 34 pts; objective response rate was 2.9%, and 50% of pts had stable disease
- Median PFS was 3.9 mo; overall survival was 9.8 mo
- Grade 3 or 4 toxicities included leukopenia/neutropenia, thrombocytopenia, elevation of aminotransferases, and fatigue
- Sunitinib rapidly decreased vessel leakiness, and this effect was more pronounced in pts with delayed progression
- When evaluated early (at baseline and d14) as well as over 3 cycles of treatment, higher levels of inflammatory molecules and circulating progenitor cells were associated with a poor outcome
Today in Hepatobiliary/Pancreas...keeping you current
Receive free subspecialty "5-minute updates" via email
Surgical management of hepatocellular carcinoma: Is the jury still out
Surgical Oncology, 11/05/09
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials
British Journal of Cancer, 11/13/09
Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report
World Journal of Surgical Oncology, 11/09/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Annals of Oncology, 11/06/09
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Vitamin D association with estradiol and progesterone in young women
Cancer Causes and Control, 11/23/09
Sponsor
Article Search
Sponsor
Sponsor